Xencor, Inc Debt Securities, Available-for-sale
Xencor, Inc (XNCR) had Debt Securities, Available-for-sale of $441.69 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale $441.69M.
- 2026-03-31: Debt Securities, Available-for-sale $527.60M.
- 2025-12-31: Debt Securities, Available-for-sale $556.76M.
- 2025-09-30: Debt Securities, Available-for-sale $605.65M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $441.69M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $527.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $556.76M 10-K · filed 2026-02-25 |
| 2025-09-30 | $605.65M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $619.38M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $653.84M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $665.80M 10-K · filed 2025-02-27 |
| 2024-09-30 | $725.32M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $554.23M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $615.33M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $643.24M 10-K/A · filed 2025-02-24 |
| 2023-09-30 | $433.25M 10-Q · filed 2023-11-08 |
| 2023-03-31 | $475.92M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $530.51M 10-K · filed 2023-02-27 |
| 2022-09-30 | $557.12M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $576.04M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $517.09M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $454.23M 10-K · filed 2022-02-24 |
| 2021-09-30 | $476.17M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $442.60M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $393.96M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $435.19M 10-K · filed 2021-02-24 |
| 2020-09-30 | $519.46M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $475.26M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $536.07M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $551.00M 10-K · filed 2020-02-25 |
| 2019-09-30 | $569.29M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $593.58M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $490.97M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $504.22M 10-K · filed 2019-02-26 |
| 2018-09-30 | $512.83M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $520.09M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $330.93M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $346.80M 10-K · filed 2018-02-28 |
| 2017-09-30 | $359.37M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $367.51M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $379.09M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $388.95M 10-Q · filed 2017-11-08 |
| 2016-09-30 | $287.09M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $160.89M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $170.57M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $180.73M 10-Q · filed 2016-11-02 |
| 2015-09-30 | $139.84M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $148.00M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $47.81M 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |